We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Experience of applying cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian teratoma with malignant transformation and peritoneal dissemination.
- Authors
Yu, Hsin-Hsien; Yonemura, Yutaka; Hsieh, Mao-Chih; Lu, Chang-Yun; Wu, Szu-Yuan; Shan, Yan-Shen
- Abstract
<bold>Objectives: </bold>The prognosis of ovarian teratoma with malignant transformation and peritoneal dissemination (PD) is poor. This condition is rare but associated with a high recurrence rate even after aggressive debulking surgery and adjuvant chemotherapy. In the present paper, we describe our experience of using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for this condition.<bold>Methods: </bold>The data of ten female patients having ovarian teratoma with malignant transformation and PD between June 2007 and June 2017 were collected and reviewed retrospectively. CRS-HIPEC was performed according to the standard protocol. Patient characteristics, pathological reports, tumor markers, perioperative operative parameters, postoperative events, and disease status during the follow-up period were recorded.<bold>Results: </bold>The primary ovarian neoplasms were pure mature cystic teratoma with malignant transformation (n=6, including 5 of mucinous adenocarcinoma), mixed germ cell tumor with mature cystic teratoma and yolk sac tumor (YST) (n=1), pure immature teratoma (n=1), immature teratoma with growing teratoma syndrome (GTS) (n=1), and immature teratoma mixed YST with GTS (n=1). The mean levels of tumor markers, including carcinoembryonic antigen, cancer antigen 19-9 (CA19-9), and CA125, were markedly elevated. The recurrence rate was 10%. The median and mean disease-free survival (DFS) after CRS-HIPEC were 22.3 and 36.2 months, respectively, and the 5-year DFS rate is 88%.<bold>Conclusion: </bold>CRS-HIPEC is a safe therapeutic option for reducing the recurrence rate in selected patients with PD originating from ovarian teratoma with malignant transformation.
- Subjects
PERITONEAL cancer; HYPERTHERMIC intraperitoneal chemotherapy; CYTOREDUCTIVE surgery; TERATOMA; COMBINED modality therapy
- Publication
Therapeutics & Clinical Risk Management, 2019, Vol 15, p129
- ISSN
1176-6336
- Publication type
journal article
- DOI
10.2147/TCRM.S190641